Aims: To elucidate if topically applied atorvastatin safely decreases corneal fluorescein staining in dry eyes associated with blepharitis.
Methods: Ten dry eye and blepharitis (DEB) patients were enroled in a prospective pilot study. All patients were treated with topical atorvastatin (50 μM) 8 times a day for 4 weeks and allowed to continue with their existing dry eye treatment. The patients were examined weekly for 4 weeks. The primary outcome measure was corneal fluorescein staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, blepharitis score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores.
Results: An improvement in corneal fluorescein staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 patients (p < 0.01). Topical atorvastatin significantly improved the tear film BUT (p < 0.01), blepharitis score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects.
Conclusion: Topical atorvastatin is a potential therapy for DEB patients. Larger comparative clinical studies are required to establish the efficacy and safety of topical atorvastatin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000367851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical atorvastatin in the management of porokeratosis.
Indian J Dermatol Venereol Leprol
November 2024
Department of Dermatology, PGIMER, Chandigarh, India.
Effect of local and systemic administration of atorvastatin for improving bone healing on critical defects.
Braz Dent J
October 2024
Department of Diagnosis and Surgery. Sao Paulo State University-Unesp. Aracatuba School of Dentistry, Sao Paulo16015-050, Brazil.
Article Synopsis
- This study investigated the effects of atorvastatin on critical bone defects in rats, with a focus on comparing local and systemic applications.
- Rats were divided into three groups: a control group receiving distilled water, a group receiving systemic atorvastatin, and a group receiving local atorvastatin, with treatments applied alongside collagen membranes.
- Results showed that systemic atorvastatin significantly reduced bone defect size and influenced bone cell activity, indicating its potential for improving bone healing while not significantly affecting inflammation.
Comparative study of orally administered seeds, hydrogel and atorvastatin on obesity of rats fed on a high fat diet.
Drug Dev Ind Pharm
July 2024
Department of Pharmaceutics, Faculty of Pharmacy, Sadat City University, Sadat City, Egypt.
Background: Obesity has become a prevalent issue worldwide, leading to various complications such as hyperlipidemia, diabetes, and cardiovascular problems. Statins, as FDA approved anti-hyperlipidemic drugs, still pose some concerns upon their administration. Recently, researchers have looked for natural products as an alternative to manage hyperlipidemia and obesity.
View Article and Find Full Text PDFTopical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.
Sci Rep
June 2024
Department of Dermatology and Venerology, Faculty of Medicine, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Cuiavian-Pomeranian, Poland.
Contemporary treatment of vitiligo remains a great challenge to practitioners. The vast majority of currently conducted clinical trials of modern therapeutic methods are focused on systemic medications, while there is only a very limited number of reports on new topical treatment in vitiligo. With their pleiotropic activities statins turned out to be efficient in the treatment of various autoimmune/autoinflammatory disorders.
View Article and Find Full Text PDFErythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Support Care Cancer
May 2024
Department of Dermatology, Stanford University, 450 Broadway St Pav B 4th Fl, Redwood City Palo Alto, CA, 94063, USA.
Introduction: Cutaneous adverse reactions to epidermal growth factor receptor inhibitors (EGFRi) are some of the most common side effects that patients experience. However, cutaneous adverse reactions that cause dyspigmentation in patients have been rarely reported. Erythema dyschromicum perstans (EDP) is a rare pigmentary condition that causes ashy-grey hyperpigmented macules and patches, with a few cases reported from EGFRi in the literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!